New hope to keep leukemia at bay after transplant
NCT ID NCT06707493
Summary
This study is testing whether a drug called ivosidenib can help prevent a specific type of leukemia (AML with an IDH1 mutation) from coming back after a patient has received a stem cell transplant. About 75 participants will be randomly assigned to receive either the study drug or a placebo for up to two years. The main goal is to see if the drug helps patients live longer without their cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH1 MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
NOT_YET_RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.